On September 23rd, Shelly and I will walk for the Jimmy Fund for our 6th consecutive year! This past summer, the experimental drug that I have been taking for more than three years (now known as ivosidenib) was approved by the FDA. My hope is that this drug--which is targeted to my specific AML mutation--will help many people like me in the future. The DFCI was one of the major centers conducting the trial, and my care team made it possible for me to get the drug even when I did not medically qualify for the protocol. This is the scientific, cutting edge, compassionate care that defines the Farber. Our walk supports the DFCI's truly remarkable cancer research and its exceptional patient-centered culture.